Laennec Injection: A 20-Year Legacy

Hello everyone! Today, let's talk about a proud product from GC Biopharma: Laennec Injection. It's been 20 years since its launch, and the cumulative shipments have now surpassed 100 million ampoules. This is a first for human placental injections in Korea, a significant achievement that holds great meaning for many.

A Celebration of Shipment and Its Significance

On the 13th, a ceremony was held at the innovative factory in Eumseong, Chungbuk, to commemorate the shipment of 100 million ampoules of Laennec Injection. This event, celebrating the product's success, garnered significant attention. Shipment volume refers to the number of products supplied from the factory to medical institutions or distributors, and may differ from actual sales figures. However, such large-scale shipments are contributing to further solidifying Laennec Injection's market position.

Laennec Injection's Effects and Usage

Laennec Injection is a prescription drug made from hydrolyzed human placenta extract. While commonly known as a 'placenta injection,' its efficacy approved by the Ministry of Food and Drug Safety is for improving liver function in chronic liver disease. Adults typically receive a 2mL injection subcutaneously or intramuscularly per dose. It's important to note that effects like fatigue relief or skin beautification are not included in its approved indications. We should keep these points in mind when considering its use, right?

Expansion Plans for the Eumseong Innovation Plant's Production Capacity

Laennec Injection is produced at the Eumseong Innovation Plant, which is equipped with automated facilities capable of producing approximately 13.5 million ampoules annually. However, GC Biopharma has announced plans to expand its production capacity to up to 25 million ampoules per year in the medium to long term to meet increasing overseas demand. While specific timelines or investment amounts have not yet been disclosed, this is a crucial decision to ensure Laennec Injection can continue to benefit many people in the future.

Challenges Towards the Future

CEO Kim Sang-hyun stated, "Exceeding 100 million cumulative shipments is a meaningful achievement." He also mentioned plans to strengthen technology and production capabilities that connect various human-derived substances, such as adipose tissue, extracellular matrix, and collagen, not just placenta, into pharmaceuticals and medical devices. This is expected to greatly contribute to future medical advancements.

As innovative products like Laennec Injection continue to emerge in the market, we can look forward to enjoying healthier and happier lives. Let's keep an eye on Laennec Injection's continued success and remember to stay informed about what you need for a healthy life!